Femara (Fe-MAR-a, letrozole), a new hormonal therapy for advanced breast cancer

September 1997

Novartis will soon launch Femara (Fe-MAR-a, letrozole), a new hormonal therapy for advanced breast cancer.

It's for postmenopausal women whose cancer progresses despite treatment with an antiestrogen such as tamoxifen (Nolvadex).

Femara is an aromatase inhibitor. Blocking this enzyme inhibits the PRODUCTION of estrogen in peripheral tissues.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Interactions between herbs and "regular" drugs
Neurology & Pain Duract (bromfenac) for pain
Cardiology Nicotine replacement therapy even for patients with coronary artery disease
Pediatrics What do you tell a parent who asks if an antibiotic tastes good?
Pediatrics Ritalin for attention deficit disorder in children with epilepsy
Pediatrics Efalex Focus, a new supplement for kids
Asthma Pulmicort Turbuhaler, a new steroid inhaler for asthma.
Diabetes Medicare will cover more diabetes supplies and services
Diabetes Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes
Vaccines New flu vaccine for this season is now in.
Osteoarthritis Two unique new treatments for osteoarthritis of the knee.
Ginkgo to improve sexual dysfunction caused by antidepressants
Actis, a new Rx device for impotence
Breast Cancer Femara (Fe-MAR-a, letrozole), a new hormonal therapy for advanced breast cancer
Psoriasis Skin-Cap is being taken off the market
Dozens of cases of thiamine deficiency
Migraine More migraine drugs will also be out in the next few months.